These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 2917360)
1. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Dowsett M; Cunningham DC; Stein RC; Evans S; Dehennin L; Hedley A; Coombes RC Cancer Res; 1989 Mar; 49(5):1306-12. PubMed ID: 2917360 [TBL] [Abstract][Full Text] [Related]
2. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Dowsett M; Goss PE; Powles TJ; Hutchinson G; Brodie AM; Jeffcoate SL; Coombes RC Cancer Res; 1987 Apr; 47(7):1957-61. PubMed ID: 3815384 [TBL] [Abstract][Full Text] [Related]
3. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report. Goss PE; Powles TJ; Dowsett M; Hutchison G; Brodie AM; Gazet JC; Coombes RC Cancer Res; 1986 Sep; 46(9):4823-6. PubMed ID: 2942241 [TBL] [Abstract][Full Text] [Related]
4. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. Celio L; Martinetti A; Ferrari L; Buzzoni R; Mariani L; Miceli R; Seregni E; Procopio G; Cassata A; Bombardieri E; Bajetta E Anticancer Res; 1999; 19(3B):2261-8. PubMed ID: 10472341 [TBL] [Abstract][Full Text] [Related]
5. Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. Johnston SR; Smith IE; Doody D; Jacobs S; Robertshaw H; Dowsett M Cancer Res; 1994 Nov; 54(22):5875-81. PubMed ID: 7954417 [TBL] [Abstract][Full Text] [Related]
6. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients. Lundgren S; Helle SI; Lonning PE Clin Cancer Res; 1996 Sep; 2(9):1515-21. PubMed ID: 9816328 [TBL] [Abstract][Full Text] [Related]
7. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen. Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984 [TBL] [Abstract][Full Text] [Related]
8. Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer. Reed MJ; Lai LC; Owen AM; Singh A; Coldham NG; Purohit A; Ghilchik MW; Shaikh NA; James VH Cancer Res; 1990 Jan; 50(1):193-6. PubMed ID: 2293555 [TBL] [Abstract][Full Text] [Related]
9. Effect of treatment with aromatase inhibitor 4-hydroxandrostenedione on the nonhuman primate menstrual cycle. Brodie AM; Hammond JO; Ghosh M; Meyer K; Albrecht ED Cancer Res; 1989 Sep; 49(17):4780-4. PubMed ID: 2758411 [TBL] [Abstract][Full Text] [Related]
10. Oral versus intramuscular high-dose medroxyprogesterone acetate (HD-MPA) in advanced breast cancer. A randomized study of the Belgian Society of Medical Oncology. Paridaens R; Becquart D; Michel J; Vanderlinden B; Longueville J; Majois F; Beauduin M; Focan C; Wildiers J; Bernheim J Anticancer Res; 1986; 6(5):1089-94. PubMed ID: 2948441 [TBL] [Abstract][Full Text] [Related]
11. Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen. Harris AL; Dowsett M; Cantwell BM; Sainsbury JR; Needham G; Farndon J; Wilson R Breast Cancer Res Treat; 1986; 7 Suppl():S69-72. PubMed ID: 2943338 [TBL] [Abstract][Full Text] [Related]
12. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ J Androl; 1998; 19(6):761-8. PubMed ID: 9876028 [TBL] [Abstract][Full Text] [Related]
13. Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A. Stein RC; Dowsett M; Davenport J; Hedley A; Ford HT; Gazet JC; Coombes RC Cancer Res; 1990 Mar; 50(5):1381-4. PubMed ID: 2137367 [TBL] [Abstract][Full Text] [Related]
14. The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients. Zilembo N; Bajetta E; Bichisao E; Martinetti A; La Torre I; Bidoli P; Longarini R; Portale T; Seregni E; Bombardieri E Biomed Pharmacother; 2004 May; 58(4):255-9. PubMed ID: 15183852 [TBL] [Abstract][Full Text] [Related]
15. In vivo effects of delta 1-testololactone on peripheral aromatization. Judd HL; Barone RM; Laufer LR; Gambone JC; Monfort SL; Lasley BL Cancer Res; 1982 Aug; 42(8 Suppl):3345s-3348s. PubMed ID: 7083208 [TBL] [Abstract][Full Text] [Related]
16. An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients. Dowsett M; Mehta A; King N; Smith IE; Powles TJ; Stein RC; Coombes RC Eur J Cancer; 1992; 28(2-3):415-20. PubMed ID: 1591054 [TBL] [Abstract][Full Text] [Related]
17. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Iveson TJ; Smith IE; Ahern J; Smithers DA; Trunet PF; Dowsett M Cancer Res; 1993 Jan; 53(2):266-70. PubMed ID: 8417819 [TBL] [Abstract][Full Text] [Related]
18. Effects of 4-hydroxyandrostenedione and hyperstimulation with pregnant mare serum gonadotrophin on early embryonic development in rats. Tong TY; Goh VH Can J Physiol Pharmacol; 2001 Sep; 79(9):744-53. PubMed ID: 11599774 [TBL] [Abstract][Full Text] [Related]
19. Plasma levels of estrone, estrone sulfate, and estradiol and the percentage of unbound estradiol in postmenopausal women with and without breast disease. Reed MJ; Cheng RW; Noel CT; Dudley HA; James VH Cancer Res; 1983 Aug; 43(8):3940-3. PubMed ID: 6683128 [TBL] [Abstract][Full Text] [Related]
20. Clinical and endocrine effects of leuprorelin acetate in pre- and postmenopausal patients with advanced breast cancer. Dowsett M; Jacobs S; Aherne J; Smith IE Clin Ther; 1992; 14 Suppl A():97-103. PubMed ID: 1606596 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]